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Abstract: Improved diagnosis and treatment regimens have resulted in greater longevity for 
men with prostate cancer. This has led to an increase in both androgen deprivation therapy (ADT) 
use and duration of exposure, and therefore to its associated adverse effects, such as sexual 
dysfunction, osteoporosis, reduced muscle mass, increased fat mass, and increased incidence of 
cardiovascular disease and type 2 diabetes. Given that the adverse effects of ADT are systemic, 
often debilitating, and difficult to treat, efforts continue in the development of new strategies 
for long-term management of prostate cancer. The PubMed database was searched to select 
trials, reviews, and meta-analyses in English using such search terms as “prostate cancer” and 
“androgen deprivation therapy”, “cardiovascular risk”, “lean body mass”, “exercise”, and “diet”. 
The initial searches produced 379 articles with dates 2005 or more recent. Articles published 
after 2004 were favored. This review utilizes the latest data to provide a status update on the 
effects of exercise and diet on patients with prostate cancer, focusing on ADT-associated side 
effects, and it discusses the evidence for such interventions. Since the evidence of large-scale 
trials in patients with prostate cancer is missing, and an extrapolation of supporting data to all 
patient subgroups cannot be provided, individualized risk assessments remain necessary before 
the initiation of exercise and diet programs. Exercise, diet, and nutritional supplementation 
interventions have the potential to provide effective, accessible, and relatively inexpensive 
strategies for mitigating ADT-associated toxicities without introducing additional adverse effects.
Keywords: androgen deprivation therapy, ADT, diet, exercise, nutrition, prostate cancer, dietary 
supplements
Introduction
Prostate cancer is the most frequently diagnosed cancer among men in developed 
countries.1 Widespread adoption of programs to screen for prostate-specific antigen 
has revolutionized the diagnosis and treatment of prostate cancer. Early detection and 
development of new treatment options have improved outcomes, increasing 5-year 
survival from 67.8% to 99.7% over the past 25 years, with 10- and 15-year survival 
presently at 99% and 94%, respectively.2 Thus, prostate cancer has moved from an 
aggressive, often fatal, disease to a chronic condition requiring comprehensive man-
agement strategies to maintain patients’ quality of life (QoL). 
Androgen deprivation therapy (ADT) has long been the frontline treatment for 
advanced prostate cancer.3–8 Indeed, over a third of the roughly 3 million men in the 
USA presently diagnosed with prostate cancer have received or are receiving ADT.2 
Although ADT has been found to improve the overall survival, it is also associated with 
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adverse side effects, including sexual dysfunction, gyneco-
mastia, hot flashes,  osteoporosis, cognitive defects, reduced 
muscle mass, increased fat mass, and increased incidence of 
both cardiovascular disease and type 2 diabetes.9–12 
Although earlier diagnosis and treatment have greatly 
extended patient longevity, they have also led to a considerably 
longer duration of ADT. An alternative, intermittent ADT has 
been proposed to mitigate the adverse effects of continuous 
ADT with the premise that it will not impact efficacy.13,14 
Although intermittent ADT offers some relief from the side 
effects of continuous ADT, in particular during treatment 
pauses, comprehensive management plans aimed at helping 
patients cope with the long-term effects of ADT throughout 
all phases of therapy are essential, but are often missing. 
Ninety percent of the patients with prostate cancer in 
the USA are aged 60 years or older,2 a population known 
to be at high risk for cardiovascular and diabetic comor-
bidities.15 Exercise and diet programs are important factors 
in reducing the risks of these conditions.16 Exercise and 
improved diet, therefore, have the potential to improve the 
QoL and also possibly the long-term survival of patients 
with prostate cancer (who may or may not be on ADT).17,18 
Some clinical trial data, including that from multiple 
randomized controlled trials, have demonstrated the abil-
ity of exercise and dietary modifications to ameliorate 
ADT-associated adverse effects, and patients and physi-
cians need to be informed about these nonpharmacologic 
approaches. Here, we review recent studies of exercise 
and nutritional interventions to assess their potential 
impact on the outcomes in patients with prostate cancer 
 receiving ADT. 
We searched the PubMed database to select trials, 
reviews, and meta-analyses in English in the last 10 years 
(2005–2015) using search terms “prostate cancer and cardio-
vascular diseases/diet/exercise/sexual dysfunction”, “andro-
gen deprivation therapy and diet/exercise/bone”, and “cancer 
and body composition”. The initial searches produced 3,863 
records after the removal of duplicates. Figure 1 shows the 
flowchart of manuscript selection.
Impact of exercise on patients with 
prostate cancer
Exercise, prostate cancer, and mortality risk
The beneficial impact of regular physical activity on many 
chronic ailments, including cardiovascular disease, osteo-
porosis, diabetes, obesity, fatigue, and depression, has been 
reported in many studies, not least in the 1996 US Depart-
ment of Health and Human Services Report of the Surgeon 
General.16 There is a paucity of good data with respect to 
the effect of exercise on the mortality of men with prostate 
cancer. Studies of cancer (including prostate cancer) have 
shown that there is a link between increased physical activity 
and improved physical functioning in cancer survivors. For 
example, the Reach out to Enhance Wellness study enrolled 
641 elderly (mean age, 73 years), sedentary, overweight, or 
obese (mean body mass index [BMI], 29 kg/m2) cancer sur-
vivors (including 94 prostate cancer survivors) and utilized 
a home-based diet and exercise intervention. The Reach out 
to Enhance Wellness intervention consisted of workbooks, 
equipment, and quarterly newsletters, endorsing 15 min-
utes of strength training every other day and 30 minutes of 
endurance exercise daily to evaluate the effects on physical 
function. The intervention produced a decrease in the rate of 
physical function decline, according to various self-reported 
measures, including the Medical Outcomes Study Short 
Form-36 (SF-36); the intervention also produced a decrease 
in BMI compared with the control (delayed intervention) 
population.19,20
Kenfield et al17 studied a population of 2,705 male health 
care professionals (mean age at prostate cancer diagnosis 
about 70 years) with nonmetastatic prostate cancer and 
found that those participating in vigorous physical activity 
(metabolic equivalent task [MET] value21 ≥6) for a duration 
≥3 hours/week demonstrated a 49% lower risk of all-cause 
mortality and a 61% lower risk of death specifically from 
prostate cancer, compared with men who did <1 hour/week 
of vigorous activity. MET value is a way of defining the 
energy cost of physical activity in adults, and examples 
range from meditation (1 MET), stationary bike or jogging 
(7 METs), playing squash (12 METs), running up stairs (15 
METs) to running at 14 mph (25 METs).17 The men engag-
ing in nonvigorous exercise (MET value <6, eg, walking 
at a normal to very brisk pace) ≥90 minutes/week had an 
all-cause mortality risk 46% less than those who walked <90 
minutes/week. There was, however, no statistically signifi-
cant difference between nonvigorous exercise and walking 
with respect to prostate cancer-specific mortality.17 Other 
studies in large populations of men who were cancer-free at 
enrollment, however, have shown no significant association 
between physical activity, body weight, and waist girth and 
prostate cancer risk,22,23 although Patel et al23 suggest that 
physical activity may be associated with reduced risk of 
aggressive prostate cancer.23
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Identification
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(n=3,868)
Included in final review
(n=101)
Figure 1 Flow diagram showing manuscript selection process.
Abbreviation: ADT, androgen deprivation therapy. 
Strength, lean body mass, and  
functional ability
A systematic review of ten studies (five randomized and five 
uncontrolled clinical trials) examined the effects of exercise 
on patients receiving ADT.24 Study populations included both 
patients with metastatic and nonmetastatic prostate cancer, 
with mean ages ranging from 63 to 72 years, and with ADT 
duration of 4 to >44 months. The number of patients on 
ADT undergoing exercise interventions ranged from five in 
a pilot study25 to 74.26 Although most interventions included 
two to six exercise-based sessions per week for 24 weeks, 
the interventions were heterogeneous, varying in duration, 
frequency, intensity, and degree of supervision. Despite this 
heterogeneity, the evidence demonstrated that physical per-
formance was improved by exercise. Randomized controlled 
trials found exercise to be consistently beneficial for muscular 
performance: reported as increases in muscular strength and 
increases in upper and lower limb strength, compared with the 
control population (see, eg, Bourke et al27 and Galvão et al28). 
Although one study found improvement in cardiovascular fit-
ness27 and others showed improvements in 400-m29 or  6-minute 
walk times,25 still other studies showed no improvement in 
6-minute walk times or in cardiorespiratory fitness.30,31
Body composition is a component of many studies inves-
tigating exercise effects on prostate cancer patients on ADT,24 
and resistance training has been shown to either increase lean 
body mass28 or reduce its decline26 in randomized controlled 
trials. Other uncontrolled studies have shown increased 
lean body mass,29 decreased BMI, or decreased weight with 
resistance exercise.29,32 The data on adiposity are not clear, 
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as some studies report an adiposity reduction,30,33 whereas 
others report no differences between exercising and control 
groups.26–28 
Fatigue
Fatigue measurements, assessed by patient-reported ques-
tionnaires, such as the Functional Assessment of Cancer 
Therapy-Fatigue (FACT-F)34 or the Functional Assess-
ment of Chronic Illness Therapy-Fatigue,35 are frequently 
assessed together with exercise outcomes in these stud-
ies.24,36,37 In general, the evidence is equivocal as to whether 
exercise helps diminish patient-reported fatigue. Some 
studies show clinically meaningful improvement versus 
controls,26,27,33,38 whereas another failed to show benefit.30 
Some uncontrolled studies show benefit; for example, Han-
son et al29 showed that in 17 black men on ADT, strength 
training reduced fatigue perception by 38%, which exceeds 
changes reported in other cancer survivor studies. On the 
other hand, for example, Hansen et al25 found that exercise 
training in ten men with prostate cancer produced no signifi-
cant difference in fatigue between those on ADT and those 
who were not. Neither of these studies was large enough 
to allow statistically meaningfully comparisons to be made 
between the groups. 
QoL
Many controlled and uncontrolled studies report that 
 physical activity improves aspects of patient-reported QoL. 
The most widely used measures for self-reported general and 
psychosocial QoL (mental health/emotional well-being) are 
the Medical Outcomes Study 12-item Short Form (SF-12) 
and the SF-36.24,39 A 3-month exercise program consisting 
of aerobic and resistance exercises produced clinically sig-
nificant improvement in the SF-36 scores of 32 men with 
prostate cancer starting ADT, compared with 31 men start-
ing ADT on usual care but not exercising.38 Likewise, in a 
pilot study, resistance exercise training sessions three times 
a week for 12 weeks produced clinically significant pros-
tate cancer-specific improvement in the QoL for five men 
on ADT, compared with those on usual care, as measured 
by the FACT-Prostate scale.25 In contrast, however, Cormie 
et al36 studied 20 men with bone metastases secondary to 
prostate cancer and found no significant between-group dif-
ferences in QoL or psychological distress comparing those 
who underwent a 12-week resistance exercise program and 
those on usual care. 
Interestingly, a study of 66 prostate cancer survivors 
compared home-based aerobic training with home-based 
resistance training and found that after 6 months, the aerobic 
group had undertaken significantly more physical activity 
than the resistance training group, although fatigue and QoL 
were not significantly different between the two groups.31 This 
suggests that aerobic exercise may be more attractive to the 
prostate cancer population than resistance exercises. This 
has implications as aerobic exercise is anticipated to have a 
greater impact on cardiovascular health, whereas resistance 
exercise is more associated with increases in muscular 
strength and lean body mass. 
Cardiovascular disease
In 2006, the Surveillance, Epidemiology, and End Results 
Medicare study reported an observed 11% increase in myo-
cardial infarction risk and a 16% increased risk of coronary 
heart disease and death from cardiac arrest in an observational 
study of prostate cancer patients receiving ADT, versus those 
not on hormone therapy (n=73,196).3 In a later study of men 
in the Veterans Healthcare Administration database, ADT was 
also found to be associated with stroke.40 These reports, along 
with observational evidence from several additional studies 
linking ADT to an increased risk of cardiovascular events, 
prompted the US Food and Drug Administration to issue a 
communication in 2010 requiring that manufacturers of drugs 
for ADT include a warning label citing an increased risk of 
diabetes and certain cardiovascular diseases (eg, heart attack, 
sudden cardiac death, and stroke) with their use.41 The link 
between ADT and cardiovascular events remains somewhat 
controversial; however, as subsequent studies indicate that 
although ADT appears to be linked to an increased risk for 
cardiovascular events, it is not associated with higher rates 
of related mortality.11,42 
Although there are no studies to date that are specifically 
powered to evaluate the effect of exercise on ADT-mediated 
cardiovascular events, there is a large body of evidence sup-
porting the role of physical activity in the prevention and 
management of cardiovascular disease in broader popula-
tions.43–46 Many plausible mechanisms could be involved in 
the protective effects of physical activity, including protec-
tion against atherosclerosis, improvement of plasma lipid 
and lipoprotein profile, dilation of peripheral blood vessels/
attenuation of sympathetic nervous activity leading to reduc-
tion in blood pressure, adaptations to coronary circulation, 
reduction in thromboses due to enhanced fibrinolysis, and 
decrease in the aggregation and adhesion of platelets.16,47,48 By 
extension, it seems likely that implementation of an exercise 
program would help mitigate the cardiovascular risk factors 
associated with ADT, although further research is necessary. 
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Bone health
Bone density reduction is a serious consequence of ADT, with 
the frequency of osteoporosis and osteopenia being directly 
proportional to treatment duration.49–51 This is particularly 
significant in men, as a high mortality rate (up to 37.5%) is 
associated with minimal trauma fractures.52 The greatest loss 
of bone mineral density occurs in the first year of ADT, with 
noticeable changes seen within months as androgen levels 
decline.53 Many epidemiologic studies have reported that low 
body weight and low BMI are risk factors for diminished bone 
mineral density and fragility fracture. An explanation for the 
correlation of higher body weight and bone resilience is that 
this may be due to increased mechanical load on the bones in 
heavier persons stimulating an increase in bone mineral den-
sity.54,55 There is considerable evidence that physical activities 
involving mechanical loading, such as resistance training and 
high-impact load-bearing exercises, are beneficial for bone 
health in the general population.16,52 In contrast to this view, 
however, a recent study of a heterogeneous cohort of 8,833 
men aged 18–64.9 years used computed tomography to show 
an inverse relationship between adiposity (BMI and visceral 
and subcutaneous adiposity) and bone quality.56 
Despite the known effects of ADT on bone health, there 
is a paucity of data available regarding the impact of exercise 
on the bone health of patients receiving ADT. Recently, a 
randomized controlled study in 63 men with prostate cancer 
examined the effect of moderate- to high-intensity aerobic 
and resistance exercises in preventing ADT-associated 
toxicity in the first 3 months of treatment and found no sig-
nificant difference in bone mineral density loss and in blood 
biomarkers of bone turnover between the exercise and usual 
care groups.38 The authors speculated that the efficacy of 
exercise-based interventions will likely require incorpora-
tion of targeted, high-impact activities that provide skel-
etal loading, such as jumping and hopping. Indeed, similar 
results have been observed in resistance training studies in 
older men and women, where only high-intensity, and not 
moderate-intensity, strength training resulted in increased 
bone mineral density.57–59 
A clinically important issue is whether high-impact or 
moderate- to high-intensity exercise might put patients with 
prostate cancer at risk of fracture, particularly in 70%–80% 
of advanced prostate cancer patients who have bone metas-
tases.60 The risk increases further given the effect that ADT 
has on bone health. For example, a study of 19,079 Canadian 
men with prostate cancer demonstrated a 65% increased fra-
gility risk for those on at least 6 months of ADT, compared 
with those not on ADT.61 Exercise, therefore, is commonly 
not  recommended for this population, due to fears over fra-
gility and potential fracture. However, a recent randomized, 
preliminary, 12-week study of targeted, moderate- to high-
intensity exercise in 20 prostate cancer patients with bone 
metastases, found that the exercise was well tolerated, with 
93% patient compliance and no reported adverse events.36 
This provides initial evidence that supervised resistance exer-
cise may be safe for prostate cancer patients with metastatic 
bone disease, although the data from this trial showed that 
the intervention made no significant changes to the patients’ 
bone mineral density. The supervised exercise did, however, 
improve other measures, such as physical activity, muscular 
strength, and lean body weight. More studies involving larger 
numbers of subjects are required to build on these results.
Sexual dysfunction
About 30%–90% of prostate cancer patients have been 
reported to experience adverse sexual side effects from their 
care treatments.62–64 Sexual dysfunction can profoundly affect 
patients’ QoL and lead to depression,  loss of connection 
with their partner, and decline in their identity as a man.62,64 
Addressing ADT complications will likely play an important 
role in improving the overall outcomes. 
Kratzik et al65 observed that in healthy men aged 45–60 
years (n=674), risk of severe erectile dysfunction was 83% 
less among men who exercised ≥3,000 kcal/week, compared 
with those who exercised ≤3,000 kcal/week. In two stud-
ies, Cormie et al38,66 examined the effect of moderate- to 
high-intensity exercise (resistance and aerobic) over a 
12-week intervention. Using the sexual function section 
of the European Organization for Research and Treatment 
of Cancer prostate cancer-specific module questionnaire, 
the researchers found significant differences between the 
usual care (nonexercise) group and the exercise group, with 
the latter reporting maintenance of sexual activity and a 
higher percentage of participants with a major interest in 
sex (17.2% vs 0%, P=0.024).38,66 In-depth interviews with 
18 men (mean age, 63.1 years) receiving ADT for prostate 
cancer suggest that exercise may be helpful in alleviating 
sexual dysfunction in a broader, less specific manner. The 
role of exercise in mitigating the reduction in lean body 
mass and muscular strength seen with ADT may be impor-
tant in improving the subjects’ perceptions of their mascu-
linity, which in turn leads to a better psychological frame 
of mind with respect to their sexuality.67 Further research is 
needed, but this preliminary data suggest that exercise may 
be able to play a role in reducing ADT-associated sexual 
dysfunction. 
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Metabolic syndrome
ADT is associated with significant adverse metabolic effects, 
including elevated serum triglycerides (≥150 mg/dL); fasting 
serum glucose ≥100 mg/dL; weight gain, especially of the 
abdomen; peripheral insulin resistance; and increased diabe-
tes risk.3,9,40,68 These effects are characteristics of metabolic 
syndrome and increase the risk of heart disease and stroke, 
in addition to diabetes.69 
We reviewed the data on cardiovascular fitness earlier, 
and there is good evidence that exercise improves or miti-
gates the decline in lean body mass and decreases the BMI 
of patients on ADT. There is also the additional evidence 
that exercise may impact the overall all-cause mortality, of 
which cardiovascular events are a large proportion. Exercise 
that is considered desirable in a noncancer population is also 
likely to show benefit in men with prostate cancer. Segal 
et al26 reported that 12 weeks of resistance training in 155 
men with prostate cancer and receiving ADT resulted in 
significantly greater upper and lower body muscular fitness, 
compared with those on usual (nonexercise) care; however, 
waist circumference, BMI, or subcutaneous adiposity differ-
ences between groups were not significant. 
Recently, two studies38,70 have shown that exercise-based 
interventions are promising methods for reducing few ADT-
specific metabolic effects. Results from a randomized pilot 
study assessed the impact of over 6 months of combined 
metformin, a low-glycemic-index diet, and exercise in 20 
prostate cancer patients at ADT initiation and compared this 
with 20 men who were on ADT alone. The metformin and 
exercise group had decreased abdominal girth, weight, BMI, 
and systolic blood pressure, compared with the group on 
ADT treatment alone, although insulin-resistant biochemical 
markers were not significantly different. In this small study, 
however, it was not possible to separate the metformin and 
dietary effects from the exercise components.70 In the study by 
Cormie et al38, 63 prostate cancer patients were randomized 
to receive either a 3-month aerobic and resistance exercise 
program or usual care, concomitant to initiation of ADT. 
Patients receiving the exercise-based intervention demon-
strated significant reductions in ADT-associated metabolic 
effects, including decreased whole body fat mass, trunk fat 
mass, and percentage fat, compared with the usual care control 
group. The ratio of total cholesterol to high-density lipoprotein 
(HDL) cholesterol improved in the exercise group, which is 
clinically significant, as this ratio is a common cardiovascu-
lar disease risk marker. There were no significant changes, 
however, in other cardiovascular and metabolic biomarkers, 
such as triglycerides, insulin and glucose levels, or glycated 
hemoglobin.38 
Evidence from trials has also shown that ADT can cause 
significant increases in HDL.38,71–73 A feature of ADT-associated 
metabolic changes is that HDL is usually elevated, which is 
not typical with metabolic syndrome (where HDL levels are 
low).72,73 Potentially, HDL increases could be further amplified 
by the addition of prescriptive exercise. Although these are 
preliminary studies, they suggest that exercise may provide 
some benefit in lessening the adverse metabolic effects of 
ADT. Two randomized trials are presently being conducted to 
investigate this further.74,75 
C-reactive protein, an inflammation marker commonly 
elevated in metabolic syndrome, showed a clinically mean-
ingful reduction in a randomized controlled trial of exercise 
in 57 men on ADT.28 Going forward, further study is required 
to investigate the correlations between C-reactive protein 
level and exercise.
Although the final verdict from large-scale trials is still 
outstanding, exercise programs should be considered an 
integral part of treatment for men with prostate cancer, as 
they can provide low-cost, scalable, and widely accessible 
strategies to help counter the systemic effects associated 
with prostate cancer therapies, including ADT. Exercise 
impacts patient well-being, both physical and psychological, 
potentially leading to improved physical functioning and 
survival.24,39,75–77 However, before a general recommendation 
can be issued, treating physicians should exercise caution 
when considering to institute exercise and diet programs, and 
patients should be carefully assessed prior to any intervention. 
Effect of nutrition and dietary 
supplements on the complications 
of ADT
Nutrition and dietary supplements
There is a lack of data on how nutritional adjustments might 
affect ADT-associated adverse effects and the few studies 
that have investigated the integration of either nutritional 
counseling or modified diet have done so in conjunction with 
another intervention, making it difficult to specifically assess 
the impact of dietary changes.70,78 Given the similarities to 
what is observed in postmenopausal women, however, some 
researchers have made specific recommendations for lifestyle 
modifications, including smoking cessation, moderation 
of alcohol and caffeine intake, and supplementation with 
vitamin D and calcium.79,80 As mentioned in the previous 
section, a low-glycemic-index diet, regular exercise, and met-
formin treatment have been shown to significantly improve 
abdominal girth, weight, BMI, and systolic blood pressure in 
patients receiving ADT.70 Caffeine is also garnering research 
as a method to potentially improve workout energy levels and 
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duration and postworkout discomfort.81 Studies with prostate 
cancer patients are lacking, although caffeine consumed 
(0.16 mg/kg anhydrous caffeine) 1 hour before completing 
a number of functional performance and exercise capacity 
tests has been reported to increase the exercise capacity by 
3.0% versus placebo in a randomized, double-blind crossover 
study in 30 prostate cancer survivors. There was no significant 
difference, however, in postexercise fatigue and perception 
of exertion compared with placebo, nor in other functional 
performance measures.82
Bone health
Despite the debilitating effects of osteoporosis observed 
in men receiving ADT, few studies have examined two key 
modulators of bone health in this population: vitamin D and 
calcium. Bone density deterioration is known to occur shortly 
after initiation of ADT.49,50 A meta-analysis of calcium and 
vitamin D studies in women and men aged ≥50 years (92% 
of study participants were women and those with secondary 
osteoporosis were excluded) provided evidence that calcium 
and vitamin D supplementation is associated with a reduced 
rate of bone mineral density loss in the hip and the spine, 
and also with decreased risk of fracture.83 On the basis of 
this evidence, the European Association of Urology has 
recommended that calcium and vitamin D supplements be 
monitored both prior to and during ADT if serum concen-
trations fall below the lower limit of normal (normal range: 
calcium, 2.2–2.6 nmol/L; vitamin D, 100–160 nmol/L).84 
In its most recent guidelines, the European Association of 
Urology recommends that a daily intake of ≥1,200 mg/day 
of calcium and 1,000 IU of vitamin D may be useful for 
improving bone mineralization in prostate cancer patients.84 
The National Osteoporosis Foundation, on the other hand, 
supports the Institute of Medicine guidelines recommend-
ing that men aged 50–70 years consume 1,000 mg/day of 
calcium, and those ≥71 years, 1,200 mg/day of calcium.85,86 
A systematic review of twelve clinical trials, however, 
failed to find conclusive support for these recommendations 
in prostate cancer patients receiving ADT, noting that the 
frequently recommended daily doses of calcium (500–1,000 
mg) and vitamin D (200–500 IU) were insufficient to pre-
vent ADT-associated bone density loss.87 More recently, in a 
prospective longitudinal study, Alibhai et al88 examined the 
long-term effects of calcium and vitamin D supplementation 
in 160 prostate cancer patients (mean age, 69 years), with and 
without ADT. Vitamin D, but not calcium, was shown to pro-
vide some protection from bone density loss, especially in the 
first year of ADT. It seems likely that the efficacy of vitamin 
D and calcium supplementation may require  implementation 
of concomitant exercise programs to stimulate bone accrual, 
as discussed earlier.36,38,75 
Fat and muscle mass
Although there are a number of randomized controlled trials 
that have demonstrated exercise to be effective for reducing 
fat mass in overweight older men,89 the absence of testos-
terone in men on ADT has proven to be a more difficult 
challenge. It has been reported that during the early phase 
of ADT, fat loss or maintenance of BMI can be achieved 
through exercise alone.38,90 This concept remains controver-
sial, however, as other studies have suggested that, in addition 
to exercise, caloric restriction is required for consistent fat 
loss in men.89,91
Loss of muscle mass, which has major consequences for 
physical function and risk of metabolic disease, is a frequently 
reported adverse effect of ADT.11 Resistance training has 
consistently been associated with muscle hypertrophy in men 
on ADT.28,31 This effect is likely to be amplified by appropri-
ate nutritional supplementation, including protein, carbohy-
drates, and creatine monohydrate, as has been demonstrated 
in studies of both younger and older men not on ADT.92 
Recently, a meta-analysis of 14 randomized controlled trials 
in a total of 626 adults showed an increase in weight loss, 
lean body mass, and a decrease in visceral fat among men 
receiving supplemental whey protein in combination with 
resistance training.93 Although more studies are needed, the 
potential for whey protein or another similar protein isolate 
to mitigate the adverse effects of prostate cancer therapies 
is considerable.
Fatigue
Encouraging data from a randomized, double-blind, phase 
III trial of American ginseng (2,000 mg/day) found a sta-
tistically significant and clinically meaningful decrease in 
cancer-related fatigue in 171 patients (4% of whom had 
prostate cancer), compared with 170 patients on placebo.94 
The primary endpoint was the Multidimensional Fatigue 
Symptom Inventory-Short Form. American ginseng is the 
first treatment option, besides exercise, to show efficacy in 
addressing cancer-related fatigue, as no other drugs, includ-
ing stimulants, have been proven to be effective. Interestingly, 
similar to what was observed with exercise,38 greater benefits 
were found in patients who started ginseng at the same time 
as their cancer treatment, compared with patients who started 
ginseng after treatment initiation. This suggests that treatment 
with American ginseng should be started at the same time or 
prior to ADT initiation; however, this needs to be confirmed 
with a larger study population of patients with prostate cancer. 
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Cardiovascular disease
The impact of ADT on cardiovascular disease development 
and progression remains contested in the literature. Regard-
less, heart disease is a leading cause of mortality in all men, 
including those on ADT.42 Lifestyle changes, such as modi-
fications to diet and exercise, may significantly affect cardio-
vascular disease risk in prostate cancer patients on ADT.18 
Although it has not been studied in patients on ADT, fish 
oil has been approved by the Food and Drug Administration for 
use in lowering triglycerides.95 Correspondingly, the American 
Heart Association recommends that individuals with heart 
disease take 1,000 mg of eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA), the primary omega-3 fatty 
acid components of fish oil, daily.96 Indeed, a large, random-
ized controlled trial (Japan EPA Lipid Intervention Study) in 
18,645 Japanese subjects has shown synergistic effects between 
omega-3 acids and statins in reducing serum  triglycerides in 
patients with high cholesterol.97,98 Interestingly, further sub-
group analysis found that fish oil significantly reduced the 
incidence of coronary artery disease in subjects with impaired 
glucose metabolism (–22%), even greater than that observed 
for subjects with normal glucose metabolism (–18%).97 
Conclusions
The advent of prostate-specific antigen screening programs, 
greater public awareness of prostate cancer, and improved treat-
ment regimens have fundamentally altered the disease landscape. 
A consequence of greater patient longevity is a more extended 
exposure to ADT and its associated adverse effects. Given that 
the adverse effects of ADT are systemic, often debilitating, and 
difficult to treat, efforts are being made in the development of 
new strategies for long-term management of prostate cancer. 
As summarized in Table 1, exercise, diet, and nutritional 
supplementation interventions have the potential to provide 
Table 1 Adverse effects reported with ADT and potential lifestyle, supplemental, and prescription medication solutions
ADT-associated 
adverse effects
Potential solutions
Exercise Diet Drugs
Anemia •	 Primarily normochromic, normocytic anemia with ADT, thus no lifestyle or supplemental options available for 
treatment99 
•	 Asymptomatic in 90% of patients, so medication is rarely, if ever, needed99 
Bone loss Resistance exercise 2–3 times a week in combination with 1,000–1,200 
mg of calcium and 800–1,000 IU of vitamin D (from food and/or 
supplements)36,51,100 
•	 Prescription medication should be 
considered based on the duration of ADT 
and documented severity of bone loss
Fatigue Resistance exercise24,38 •	 Caffeine from beverages 
(general stimulant)81
•	 American ginseng (2,000 mg/
day at 3%–5% ginsenosides)94
Hot flashes Maintaining a healthy weight may 
reduce the severity of vasomotor 
symptoms and moderate aerobic 
exercise could also be beneficial
No dietary supplement has 
demonstrated a consistent 
benefit over placebo101
•	 Prescription medication can be effective 
(eg, megestrol acetate, venlafaxine) for 
moderate-to-severe QoL – altering hot 
flashes101
Lipids and/or prediabetes
(elevated cardiovascular 
risk)
•	 ADT has controversial 
cardiovascular risk data18
•	 Diet and exercise80
•	 Abnormal glucose levels may 
respond to diet and exercise70
Omega-3 fatty acids (EPA/DHA; 
500 mg/dL or more) FDA-
approved for hypertriglyceridemia 
only (although studies lack clinical 
endpoints)95–98
•	 When appropriate, low-dose statin and/or 
ezetimibe prescription treatment; low-dose 
aspirin for those who qualify, based on 
overall cardiovascular risk80 
•	 When appropriate, prescription metformin 
has preliminary data with ADT70
Sarcopenia Resistance exercise 2–3 times per week in addition to calcium and 
vitamin D recommended daily intake (as for bone loss)28,92
•	 Preliminary indirect evidence 
suggests that whey protein 
isolate (or another protein 
isolate) at 20–25 g per day 
could also assist with muscle 
protein synthesis93
Weight gain (visceral 
adipose tissue 
accumulation)
Diet and aerobic and resistance 
exercise24,38
Whey protein isolate may also 
assist with appetite suppression93
•	 Metformin (850 mg twice a day) has 
preliminary data for weight loss with ADT70
Notes: Not all the adverse events listed in this table are discussed in this review. We refer the reader to the scientific literature for more detailed discussions of these.
Abbreviations: ADT, androgen deprivation therapy; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; FDA, US Food and Drug Administration; IU, international 
unit; QoL, quality of life.
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relatively inexpensive and accessible strategies for mitigating 
many ADT-associated toxicities and are unlikely to introduce 
additional adverse effects. However, since the evidence of 
large-scale trials in patients with prostate cancer is miss-
ing, and an extrapolation of supporting data to all patient 
subgroups cannot be provided, individualized risk assess-
ments remain necessary before the initiation of exercise 
and diet programs. The coordinated efforts of health care 
p rofessionals, including exercise physiologists and dieticians, 
coupled with increased patient awareness, will be critical for 
effective implementation of such intervention programs, and 
future research would help to further our understanding of 
the effectiveness of diet and exercise in this complex patient 
population. 
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